If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...
Explore opportunities with Novartis below.
Job Title Sort ascending Business Location Site Date Posted Equipment Specialist (m/w/d), Kundl, Tirol, Österreich Regulär, Full time Innovative Medicines Austria Kundl Oct 18, 2024 Trainee Marketing ...
Below is a list of the treatments we currently offer via our Innovative Medicines Division. Visit Sandoz and Advanced Accelerator Applications to learn about our generics and radiopharmaceutical ...
The Drug Supply Chain Security Act (DSCSA) is federal legislation passed in 2013 that creates national requirements for tracing pharmaceutical products throughout the entire supply chain. This new ...
Scientist - Technical Development (m/f/d) Regulär, Full time Innovative Medicines Switzerland Basel (City) 17 Oktober 2024 MR Regular (Sales), Full time Innovative Medicines China Changsha (Hunan ...
ノバルティス ファーマ株式会社（本社：東京都港区、以下「ノバルティス ファーマ」）の代表取締役社長に、2024年11月1日付で、ジョンポール・プリシーノ（John Paul Pullicino）が就任すること ...
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...
诺华 承 诺 与残障人士共事并 为 他 们 提供合理的便利 设 施。如果您由于健康状况或残障 在招聘 过 程的任何 环 节 需要合理便利 设 施 或者 为 了履行 职 位的基本 职 能 请发 送 电 子 邮 件 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback